Results 121 to 130 of about 98,340 (384)
Advanced Experiment Design Strategies for Drug Development
Advanced Intelligent Discovery, EarlyView.Wang et al. analyze 592 drug development studies published between 2020 and 2024 that applied design of experiments methodologies. The review surveys both classical and emerging approaches—including Bayesian optimization and active learning—and identifies a critical gap between advanced experimental strategies and their practical adoption in ...
Fanjin Wang +3 more
wiley +1 more source
Immunogenicity of Biopharmaceuticals [PDF]
IOSR Journal of Pharmacy (IOSRPHR), 2012 Modern biotechnology has resulted in a resurgence of interest in the production of new therapeutic agents using botanical sources. With nearly 500 biotechnology products approved or in development globally, and with production capacity limited, the need for efficient means of therapeutic protein production is apparent.
openaire +1 more source
Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges
Animal Models and Experimental Medicine, EarlyView.Abstract Respiratory infectious diseases frequently erupt on a global scale, with RNA viruses, such as SARS‐CoV‐2, RSV, and influenza viruses, posing challenges to vaccine development due to their high mutation rates. Traditional vaccine development cycles are lengthy and struggle to keep pace with rapidly evolving viruses, whereas messenger RNA (mRNA)
Linlin Zheng, Han Feng
wiley +1 more source
Editorial: Separation Processes in Pharmaceutical Manufacturing
Frontiers in Chemical Engineering, 2022 Cristina Chuck-Hernández +4 more
doaj +1 more source
From Business model to Business model portfolio in the european biopharmaceutical industry [PDF]
At the crossroad of firm's core competencies and of the anticipations of consumers' needs, the business model approach complements corporate and business strategy approaches.
Tristan Rouselle +2 more
core
The Future of Generic Biologics: Should the United States “Follow-On” the European Pathway? [PDF]
, 2008 The United States is embarking on a biotechnology drug revolution. In the last few decades, biotech drugs have saved millions of lives, and the market for these miracle cures continues to grow at an astronomical rate.
Kaldre, Ingrid
core +1 more source
Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy
Annals of Neurology, EarlyView.Objective Exenatide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, has neuroprotective effects in preclinical models of multiple system atrophy (MSA). We investigated these effects in a proof‐of‐concept clinical trial. Methods In this single‐center, randomized, open label trial, participants with MSA were randomly assigned (1:1) to receive ...
Nirosen Vijiaratnam +29 more
wiley +1 more source
Do Firms Benefit from Being Present in Multiple Technology Clusters? An Assessment of the Technological Performance of Biopharmaceutical Firms [PDF]
Firms active in knowledge-intensive fields are increasingly organizing their R&D activities on an international scale. This paper investigates whether firms active in biotechnology can improve their technological performance by developing R&D activities ...
Bart Leten +3 more
core
Manufacturing Barriers to Biologics Competition and Innovation [PDF]
, 2016 As finding breakthrough small-molecule drugs gets harder, drug companies are increasingly turning to “large molecule” biologics. Although biologics represent many of the most promising new therapies for previously intractable diseases, they are extremely
Price, W. Nicholson, II, Rai, Arti K.
core +2 more sources
Arthritis &Rheumatology, Accepted Article.Objective The Phase 3 MANDARA study demonstrated non‐inferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair +14 more
wiley +1 more source